Dr William Camu graduated as an MD and specialist in Neurology in 1989, at the Faculty of Medicine of Montpellier, France. He started his research on ALS in 1986 and has never given up to try to find a cure for ALS. In 1999 he became a Professor of Neurology at the Faculty and University hospitals of Montpellier. After he developed a method of purification for motoneuron cultures in the Christopher Henderson’s lab, he oriented his work on genetics with large and fruitful collaborations. The motoneuron team he is still heading, was labelled as a national expert ALS center in 2003. Prof. Camu is also heading the Clinical Neurophysiology department of the University Hospital Gui de Chauliac in Montpellier since 2005. His expertise covers clinical neurology, genetics, biomarkers and clinical research, including clinical trials. He has published more than 200 articles in referenced journals.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.